C-peptide response in patients on insulin therapy

Area of Science:

• Endocrinology
• Metabolic Diseases
• Clinical Research

Background:

• Type I diabetes (T1D) is an autoimmune disease characterized by insulin deficiency.
• Understanding the clinical presentation and beta-cell function in T1D is crucial for diagnosis and management.
• Insulin-treated diabetes can encompass both Type I and Type II forms, necessitating diagnostic differentiation.

Purpose of the Study:

• To document the clinical features and presentation of Type I diabetes.
• To investigate the beta-cell response in insulin-treated diabetic patients.
• To explore the utility of C-peptide response in differentiating Type I from Type II diabetes.

Main Methods:

• Retrospective analysis of clinical data from 30 insulin-treated patients.
• Assessment of clinical features including age of onset, family history, and diabetic complications.
• Measurement of C-peptide response to glucose challenge to evaluate residual beta-cell function.

Main Results:

• Type I diabetes most commonly presents in the 20-40 year age group.
• Common complications included retinopathy (63%) and peripheral neuropathy (53%).
• Three distinct C-peptide response patterns were observed: no response, blunted response, and low-normal peak response, with the latter potentially indicating Type II diabetes.

Conclusions:

• C-peptide response is a valuable tool for differentiating Type I from Type II diabetes in insulin-treated patients.
• Clinical features and complications vary, but C-peptide assessment offers a functional measure for classification.
• Further research into the low-normal C-peptide response group is warranted to confirm Type II diabetes classification.